Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

FY2027 EPS Estimates for Amgen Reduced by Erste Group Bank

AI-generated analysis

📉 Erste Group Bank lowered FY2027 EPS estimates for Amgen to $23.58 from $23.62 while maintaining a 'Hold' rating.

📈 The company beat Q1 earnings expectations with $5.15 EPS and revenue of $8.62 billion, exceeding the consensus of $4.77 EPS and $8.58 billion.

💰 Amgen reported a net margin of 20.96% and a return on equity of 137.41% during the quarter ended April 30th.

🎯 Full-year 2026 guidance stands at $21.70-$23.10 EPS, with revenue up 5.8% year-over-year to $8.62 billion.

🏦 Morgan Stanley reduced its price target to $333.00 and set an 'equal weight' rating on the stock.

📊 Royal Bank of Canada reissued a 'positive' rating, while Piper Sandler reiterated an 'overweight' recommendation.

📉 Truist Financial raised its price target to $340.00 but maintained a 'Hold' rating on the shares.

🏛️ Institutional investors own 76.50% of the company's outstanding stock as of the latest filings.

📉 SVP Nancy A. Grygiel sold 1,237 shares for approximately $400,454 in a transaction disclosed to the SEC.

📈 The stock trades at a PEG ratio of 3.76 with a market capitalization of $197.69 billion.

Bullish Signals
  • Amgen beat quarterly earnings estimates significantly, reporting $5.15 EPS versus the consensus of $4.77.
  • Revenue grew 5.8% year-over-year to $8.62 billion, surpassing analyst expectations of $8.58 billion.
  • The company demonstrated strong profitability with a net margin of 20.96% and an impressive return on equity of 137.41%.
  • Royal Bank of Canada has reissued a 'positive' rating on the stock, signaling continued confidence in the business model.
  • Piper Sandler reiterated its 'overweight' rating, indicating sustained bullish sentiment from major investment banks.
  • Truist Financial increased its price target to $340.00, reflecting optimism regarding future performance potential.
Risk Factors
  • Erste Group Bank reduced its FY2027 EPS forecast to $23.58, indicating a slight downgrade in long-term growth expectations.
  • Morgan Stanley lowered its price target from $340.00 to $333.00 and adjusted its rating to 'equal weight', suggesting caution.
  • Weiss Ratings downgraded the stock from a 'buy (b)' to a 'buy (b-)', reflecting a minor reduction in investment grade status.
  • SVP Nancy A. Grygiel sold 1,237 shares for $400,454, representing a 15% decrease in her personal ownership stake.
Full Analysis
Equities research analysts at Erste Group Bank have reduced their full-year 2027 earnings per share (EPS) estimate for Amgen Inc. to $23.58, down from a previous forecast of $23.62. The analyst maintains a 'Hold' rating on the stock, which currently trades with a consensus EPS estimate of $22.31. This adjustment reflects a slight downward revision in long-term growth expectations for the biotechnology company. Amgen recently reported strong quarterly results for the quarter ended April 30th, posting EPS of $5.15 against a consensus of $4.77 and revenue of $8.62 billion, beating expectations of $8.58 billion. The company achieved a net margin of 20.96% and a return on equity of 137.41%, with revenue growing 5.8% year-over-year. Management has set full-year 2026 guidance between $21.70 and $23.10 per share. Analyst sentiment remains mixed, with Royal Bank of Canada reaffirming a 'positive' rating while Morgan Stanley lowered its price target to $333.00 and Piper Sandler reiterated an 'overweight' stance. The stock currently has an average analyst rating of 'Hold' with a price target of $356.62, trading near its 50-day moving average of $347.69.